Negative ER Expression Assessed by 18F-FES PET/CT in the MBC With ER-positive Primary Tumor
To investigate the treatment pattern and efficacy of patients with positive primary ER lesion but negative ER expression in MBC using a novel convenient way of 18F-fluoroestradiol positron emission tomography/computed tomography (18F-FES PET/CT).
Breast Cancer
Progression free survival (PFS), 6 weeks
Adverse events, Number of participants with treatment-related adverse events as assessed by CTCAE v 5.0, 6 weeks
To investigate the treatment pattern and efficacy of patients with positive primary ER lesion but negative ER expression in MBC using a novel convenient way of 18F-fluoroestradiol positron emission tomography/computed tomography (18F-FES PET/CT).